SeraNovo enters license agreement with Carna Biosciences to develop an oral formulation of Carna’s kinase inhibitor

SeraNovo has announced that it has signed a second license agreement with Carna Biosciences, Inc., a company engaged in the drug development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly develop an oral formulation of a new active ingredient with an enhanced bioavailability.

Utilizing its proprietary Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability. The DES formulation platform is based on GRAS excipients that are used for oral administration and broadly used in the industry.

Niall Hodgins, CEO of SeraNovo commented: “After our initial license announcement in October 2019, we are pleased to extend our relationship with Carna to include the formulation of another promising active ingredient. This expansion of our partnership with an industry leader is a great development towards widespread adoption of our breakthrough formulation technology.”

For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>